1. Circulating Amino Acids and Risk of Peripheral Artery Disease in the PREDIMED Trial
- Author
-
Cristina Razquin, Miguel Ruiz-Canela, Estefania Toledo, Clary B. Clish, Marta Guasch-Ferré, Jesús F. García-Gavilán, Clemens Wittenbecher, Angel Alonso-Gómez, Montse Fitó, Liming Liang, Dolores Corella, Enrique Gómez-Gracia, Ramon Estruch, Miquel Fiol, Jose M. Santos-Lozano, Luis Serra-Majem, Emilio Ros, Fernando Aros, Jordi Salas-Salvadó, Frank B. Hu, Miguel A. Martínez-González, [Razquin, Cristina] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Ruiz-Canela, Miguel] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Toledo, Estefania] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Martinez-Gonzalez, Miguel A.] Univ Navarra, Dept Prevent Med & Publ Hlth, IdiSNA Inst Invest Sanitaria Navarra, Pamplona 31008, Spain, [Razquin, Cristina] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Ruiz-Canela, Miguel] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Toledo, Estefania] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Garcia-Gavilan, Jesus F.] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Alonso-Gomez, Angel] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Fito, Montse] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Corella, Dolores] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Estruch, Ramon] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Fiol, Miquel] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Santos-Lozano, Jose M.] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Serra-Majem, Luis] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Ros, Emilio] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Aros, Fernando] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Salas-Salvado, Jordi] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Martinez-Gonzalez, Miguel A.] Inst Salud Carlos III, CIBER Fisiopatol Obes & Nutr CIBERObn, Madrid 28029, Spain, [Clish, Clary B.] Harvard Univ, Broad Inst MIT, Cambridge, MA 02142 USA, [Guasch-Ferre, Marta] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Wittenbecher, Clemens] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Hu, Frank B.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Martinez-Gonzalez, Miguel A.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA, [Guasch-Ferre, Marta] Univ Copenhagen, Dept Publ Hlth, Sect Epidemiol, DK-1165 Copenhagen, Denmark, [Guasch-Ferre, Marta] Univ Copenhagen, Novo Nord Fdn Ctr Basic Metab Res, DK-1353 Copenhagen, Denmark, [Garcia-Gavilan, Jesus F.] Univ Rovira i Virgili, Dept Bioquim & Biotecnol, Unitat Nutr Humana, Reus 43201, Spain, [Salas-Salvado, Jordi] Univ Rovira i Virgili, Dept Bioquim & Biotecnol, Unitat Nutr Humana, Reus 43201, Spain, [Garcia-Gavilan, Jesus F.] Hosp Univ San Joan Reus, Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain, [Salas-Salvado, Jordi] Hosp Univ San Joan Reus, Inst Invest Sanitaria Pere Virgili IISPV, Reus 43204, Spain, [Wittenbecher, Clemens] Chalmers Univ Technol, Dept Biol & Biol Engn, Food & Nutr Sci Div, SciLifeLab, SE-41296 Gothenburg, Sweden, [Alonso-Gomez, Angel] Univ Basque Country UPV EHU, Araba Univ Hosp, Bioaraba Hlth Res Inst, Osakidetza Basque Hlth Serv, Vitoria 01009, Spain, [Aros, Fernando] Univ Basque Country UPV EHU, Araba Univ Hosp, Bioaraba Hlth Res Inst, Osakidetza Basque Hlth Serv, Vitoria 01009, Spain, [Fito, Montse] Inst Hosp del Mar Invest Med IMIM, Unit Cardiovasc Risk & Nutr, Barcelona 08003, Spain, [Liang, Liming] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02115 USA, [Corella, Dolores] Univ Valencia, Dept Prevent Med, Valencia 46100, Spain, [Gomez-Gracia, Enrique] Univ Malaga, Dept Prevent Med, Malaga 29071, Spain, [Estruch, Ramon] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Dept Internal Med, Barcelona 08036, Spain, [Fiol, Miquel] Hosp Univ Son Espases, Plataforma Ensayos Clin, Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca 07120, Spain, [Santos-Lozano, Jose M.] Dist Sanitario Atenc Primaria Sevilla, Dept Family Med, Res Unit, Seville 41013, Spain, [Serra-Majem, Luis] Univ Las Palmas Gran Canaria, Res Inst Biomed & Hlth Sci IUIBS, Nutr Res Grp, Las Palmas Gran Canaria 35016, Spain, [Ros, Emilio] Univ Barcelona, Hosp Clin, Agust Pi Sunyer Biomed Res Inst IDIBAPS i, Dept Endocrinol & Nutr,Lipid Clin, Barcelona 08036, Spain, and [Hu, Frank B.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA
- Subjects
PREDIMED ,amino acids ,Predictors ,Organic Chemistry ,General Medicine ,case-cohort ,peripheral artery disease ,metabolomics ,Catalysis ,Computer Science Applications ,Association ,Inorganic Chemistry ,Life ,Health ,Physical and Theoretical Chemistry ,Ratio ,Molecular Biology ,Spectroscopy - Abstract
Effective prevention and risk prediction are important for peripheral artery disease (PAD) due to its poor prognosis and the huge disease burden it produces. Circulating amino acids (AA) and their metabolites may serve as biomarkers of PAD risk, but they have been scarcely investigated. The objective was to prospectively analyze the associations of baseline levels of plasma AA (and their pathways) with subsequent risk of PAD and the potential effect modification by a nutritional intervention with the Mediterranean diet (MedDiet). A matched case-control study was nested in the PREDIMED trial, in which participants were randomized to three arms: MedDiet with tree nut supplementation group, MedDiet with extra-virgin olive oil (EVOO) supplementation group or control group (low-fat diet). One hundred and sixty-seven PAD cases were matched with 250 controls. Plasma AA was measured with liquid chromatography/mass spectrometry at the Broad Institute. Baseline tryptophan, serine and threonine were inversely associated with PAD (ORfor 1 SD increase = 0.78 (0.61–0.99); 0.67 (0.51–0.86) and 0.75 (0.59–0.95), respectively) in a multivariable-adjusted conditional logistic regression model. The kynurenine/tryptophan ratio was directly associated with PAD (ORfor 1 SD increase = 1.50 (1.14–1.98)). The nutritional intervention with the MedDiet+nuts modified the association between threonine and PAD (p-value interaction = 0.018) compared with the control group. However, subjects allocated to the MedDiet+EVOO group were protected against PAD independently of baseline threonine. Plasma tryptophan, kynurenine/tryptophan ratio, serine and threonine might serve as early biomarkers of future PAD in subjects at a high risk of cardiovascular disease. The MedDiet supplemented with EVOO exerted a protective effect, regardless of baseline levels of threonine.
- Published
- 2022